Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 15/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661470 | 0.87 | AHR (0.38) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL13000534 | 0.84 | AHR (0.37) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL29508980 | 0.79 | CYP3A4 (0.53) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL10311723 | 0.78 | AHR (0.40) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL28744259 | 0.74 | CYP3A4 (0.53) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL29857997 | 0.74 | CYP3A4 (0.53) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL29629138 | 0.74 | CYP3A4 (0.53) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL30681699 | 0.73 | CYP3A4 (0.50) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL10524296 | 0.73 | AHR (0.41) | CYP3A4AHRHPGDHSD17B10TSHR | |
| SCHEMBL30485634 | 0.72 | ALDH1A1 (0.55) | CYP3A4AHRHPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796456-B2 | Naphthalene diimide compounds | UNIVERSITY COLLEGE LONDON (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2227470-B1 | NAPHTHALENE DIIMIDE COMPOUNDS INTERACTING WITH G-QUADRPLEX REGIONS IN DNA | UNIV LONDON (GB) | 2014-03-05 | — | — | EP | disclosed |
| US-20100311739-A1 | Naphthalene Diimide Compounds | UNIVERSITY COLLEGE LONDON (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2227470-A1 | NAPHTHALENE DIIMIDE COMPOUNDS INTERACTING WITH G-QUADRUPLEX REGIONS IN DNA | THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068916-A1 | NAPHTHALENE DIIMIDE COMPOUNDS INTERACTING WITH G-QUADRUPLEX REGIONS IN DNA | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311739-A1 | Naphthalene Diimide Compounds | NDC1, NUTF2, NDUFC2 | CYP3A4 821/4885AHR 127/4885HPGD 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.